Clinical Trial Update: Rasburicase (Fasturtec) Registration Trial [Phase 3]

View source ↗

Summary

Phase 3 Rasburicase registration trial (Fasturtec) for hyperuricemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia

Drugs mentioned

• Fasturtec (rasburicase)

Snippet

Sponsor: Sanofi | Conditions: Hyperuricemia | Phase 3 | Status: TERMINATED